Curiva
Private Company
Funding information not available
Overview
Curiva is an early-stage diagnostics company pioneering a novel, non-invasive wearable patch (diaPatch™) designed to triage patients after an abnormal Pap smear. The patch uses microneedles to sample interstitial fluid from the lower abdomen and a molecular assay to detect tumor-associated biomarkers, targeting results within 30 minutes during the same clinical visit. Founded in 2018 and headquartered in Goshen, Indiana, with a presence in Chicago and San Diego, the company is pre-revenue and in the development stage, currently fundraising and planning regulatory pathways. Its initial focus is cervical cancer, with future potential in other gynecologic cancers.
Technology Platform
Wearable diagnostic patch combining microneedles for interstitial fluid sampling with an integrated molecular assay for biomarker detection (e.g., microRNA), targeting same-visit results.
Opportunities
Risk Factors
Competitive Landscape
Competition includes traditional Pap smear cytology and HPV DNA testing, as well as emerging liquid biopsy tests for cervical cancer (e.g., from Roche, Qiagen, Becton Dickinson). Curiva's primary differentiation is its non-invasive, wearable, same-visit form factor, which is first-in-class for this indication. It must compete on clinical performance, cost, and ease of use against both entrenched standards and other novel molecular assays.